Trial Profile

An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brolucizumab (Primary) ; Aflibercept
Indications Retinal oedema; Retinal vein occlusion; Vision disorders
Focus Registrational; Therapeutic Use
Acronyms RAVEN
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals

19 Dec 2022 This trial has been Suspended in Italy, Greece, Netherland and Germany according to European Clinical Trials Database record.
11 Aug 2021 This trial has been completed in Hungary (Global end date: 26 July 2021) according to European Clinical Trials Database record.
05 Aug 2021 This trial has been completed in Finland, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com